A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Participants With Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments (ELEVATE)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prophylaxis of Migraine in Participants With Episodic Migraine Who Have Previously Failed 2 to 4 Classes of Oral Prophylactic Treatments (ELEVATE)
This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in participants with episodic migraine and who have previously failed 2 to 4 classes of oral prophylactic treatments.
Inclusion Criteria:
Exclusion Criteria:
Encino, California 91316, United States
Los Alamitos, California 90720-3500, United States
Los Alamitos, California 90720-3500, United States
Fort Wayne, Indiana 46804, United States
Saint Priest EN Jarez, Pays de la Loire Region 42270, France
Lublin, Lublin Voivodeship 20-582, Poland
Valledolid, Castellon 47005, Spain